1. < Home

Drug resistance

Editorial: Developing next-generation therapeutics to defeat mutation-driven cancer

Chow F, Lamoureux F, Moriceau G. Editorial: Developing next-generation therapeutics to defeat mutation-driven cancer. Front Immunol. 2024 Sep 26;15:1487952. doi: 10.3389/fimmu.2024.1487952. PMID: 39391312; PMCID: PMC11464455.

By sjmartinez • October 11, 2024
Virological Findings and Treatment Outcomes of Cases That Developed Dolutegravir Resistance in Malawi’s National HIV Treatment Program

Kanise H, van Oosterhout JJ, Bisani P, Songo J, Matola BW, Chipungu C, Simon K, Cox C, Hosseinipour MC, Sagno JB, Hoffman RM, Wallrauch C,[...]

By sjmartinez • January 23, 2024
Nosocomial Infections by Diverse Carbapenemase-producing Aeromonas hydrophila Associated with Combination of Plumbing Issues and Heat Waves

Gray HK, Bisht A, Caldera JR, Fossas Braegger NM, Cambou MC, Sakona AN, Beaird OE, Uslan DZ, Walton SC, Yang S. Nosocomial Infections by Diverse[...]

By sjmartinez • October 2, 2023
Transient SARS-CoV-2 RNA-Dependent RNA Polymerase Mutations after Remdesivir Treatment for Chronic COVID-19 in Two Transplant Recipients: Case Report and Intra-Host Viral Genomic Investigation

Yang S, Multani A, Garrigues JM, Oh MS, Hemarajata P, Burleson T, Green NM, Oliai C, Gaynor PT, Beaird OE, Winston DJ, Seet CS, Schaenman[...]

By sjmartinez • August 27, 2023
m6A-modification of cyclin D1 and c-myc IRESs in glioblastoma controls ITAF activity and resistance to mTOR inhibition

Benavides-Serrato A, Saunders JT, Kumar S, Holmes B, Benavides KE, Bashir MT, Nishimura RN, Gera J. m6A-modification of cyclin D1 and c-myc IRESs in glioblastoma[...]

By sjmartinez • April 16, 2023